IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FU
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Colorectal Carcinoma
Conditions
Colorectal Carcinoma
Trial Timeline
Apr 1, 2009 → Aug 1, 2011
NCT ID
NCT00862784About IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FU
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FU is a phase 2 stage product being developed by Eli Lilly for Colorectal Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00862784. Target conditions include Colorectal Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00862784 | Phase 2 | Completed |
Competing Products
20 competing products in Colorectal Carcinoma